Eirgen Pharma, A Waterford Success Story - 20 Years in the Making
Eirgen Pharma is celebrating 20 years since its establishment in Waterford. The company, which was founded in 2005 by Patsy Carney and Tom Brennan, has grown into a globally recognised centre of excellence in high-potency pharmaceutical development, manufacturing and packaging, with partners in over 60 countries.
Eirgen has been operating in Waterford’s since 2005, where it established its expertise in high-potency oral solid dose (OSD) medicines, specialising in oncology treatments and rare diseases. The company’s rise has been nothing short of remarkable. Over the years, it has expanded its expertise, adding advanced manufacturing capabilities and a growing portfolio of pharmaceutical solutions for both human and veterinary medicine including, cardiovascular health, and immunodeficiency therapies. The company’s commitment to innovation and quality, quickly positioned it as a trusted partner in the pharmaceutical industry, leading to its first U.S FDA approval within just a year of its founding.
A Global Footprint with Local Roots
Eirgen Pharma has since expanded its global footprint, developing partnerships with major pharmaceutical companies and extending its reach into key international markets, including the United States, Japan, Australia, Canada, and the Middle East. The company is now recognized as a trusted contract development and manufacturing (CDMO) partner, specializing in high-containment drug formulation and advanced manufacturing technologies.
While Eirgen’s influence spans across the globe, Waterford remains its home and operational hub. The company, now employing over 150 highly skilled professionals, has played a key role in developing local talent and fostering innovation within the region.
As part of its continued investment in Waterford and to meet the demands of an international dynamic market, Eirgen Pharma has announced the development of a new state-of-the-art 3,500m2 manufacturing facility at the IDA Industrial Estate, due to launch for commercialisation later this year. This expansion will increase production capacity, allowing the company to introduce pharmaceutical solutions while reinforcing its commitment to job creation and economic growth in the region.
“Waterford is where Eirgen was founded, and it remains the heart of our operations,” said Damien Burke, CEO of Eirgen Pharma. “This latest investment reflects our long-term commitment to the region. By upgrading our facilities and expanding our capabilities, we are ensuring that Waterford continues to be a global leader in pharmaceutical innovation.”
A Legacy of Innovation and Excellence
Eirgen Pharma’s success has been driven by its focus on research, development, and technological advancement. The company has established itself as a specialist in high-containment drug development, working with cytotoxic and genotoxic formulations to produce life-changing medicines.
Its cutting-edge facilities include closed-loop iso
lators, powder containment booths, and advanced air filtration systems, ensuring the highest levels of safety, efficiency, and regulatory compliance. These innovations have positioned Eirgen as a preferred manufacturing partner for some of the world’s largest pharmaceutical companies.
The company’s growth was further accelerated in 2015 when it was acquired by OPKO Health, a Miami-based multinational healthcare company. This partnership has provided Eirgen with additional resources, expertise, and international networks, allowing it to scale its operations while maintaining its Waterford roots.
A Commitment Beyond Business
Beyond its pharmaceutical achievements, Eirgen Pharma has remained committed to supporting the local community. Over the years, the company has been an active supporter of local charities and initiatives, recognising the importance of corporate social responsibility. Most recently, Eirgen donated €20,000 to the SOLAS Cancer Support Centre, a vital resource for individuals and families affected by cancer.
Looking to the Future
As Eirgen Pharma enters its third decade, it remains focused on innovation, expansion, and global impact. The company is committed to expanding its research and development efforts to deliver new pharmaceutical solutions, enhancing its manufacturing capabilities through continued investment in technology and infrastructure, strengthening global partnerships to improve patients’ lives, growing its team, and creating high-value career opportunities in Waterford and beyond.
“The future of Eirgen Pharma is one of continued growth and innovation,” says Damien Burke. “As we celebrate 20 years of success, we are more determined than ever to push the boundaries of pharmaceutical development, improve patient health, and ensure that Waterford remains a centre of excellence in the industry.”
With a solid foundation, commitment to excellence, and a clear vision for the future, Eirgen Pharma is poised to continue shaping the next generation of pharmaceutical development and manufacturing - right from the heart of Waterford.
Eirgen Pharma
Westside Business Park
Old Kilmeaden Road
Waterford.
X91 YV67
www.eirgen.com
